ChromaDex (NASDAQ:CDXC) Earns Buy Rating from HC Wainwright

ChromaDex (NASDAQ:CDXC)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $11.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 40.31% from the company’s current price.

Several other equities analysts have also recently commented on the stock. LADENBURG THALM/SH SH increased their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th.

ChromaDex Price Performance

CDXC opened at $7.84 on Monday. ChromaDex has a 12-month low of $2.02 and a 12-month high of $9.18. The stock has a market capitalization of $609.56 million, a PE ratio of 784.78 and a beta of 2.21. The firm’s fifty day moving average price is $6.01 and its 200 day moving average price is $5.36.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new stake in ChromaDex during the fourth quarter worth about $555,000. Two Sigma Investments LP bought a new position in shares of ChromaDex during the fourth quarter valued at approximately $675,000. State of Wyoming acquired a new stake in shares of ChromaDex during the 4th quarter worth approximately $39,000. Sherbrooke Park Advisers LLC bought a new stake in shares of ChromaDex in the 4th quarter worth approximately $94,000. Finally, ProShare Advisors LLC acquired a new position in ChromaDex during the 4th quarter valued at approximately $74,000. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.